Form 8-K - Current report:
SEC Accession No. 0001104659-22-038081
Filing Date
2022-03-25
Accepted
2022-03-25 16:07:51
Documents
13
Period of Report
2022-03-25
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2210389d1_8k.htm   iXBRL 8-K 28838
2 EXHIBIT 16.1 tm2210389d1_ex16-1.htm EX-16.1 2818
  Complete submission text file 0001104659-22-038081.txt   206310

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inva-20220325.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inva-20220325_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inva-20220325_pre.xml EX-101.PRE 22587
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2210389d1_8k_htm.xml XML 3604
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30319 | Film No.: 22771423
SIC: 2834 Pharmaceutical Preparations